Investigating cell therapy for inflammatory bowel disease

Expert Opinion on Biological Therapy

Volumn 16, Issue 8, 2016, Pages 1015-1023

  Okamoto, Ryuichi ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

hematopoietic stem cells; Inflammatory bowel disease; intestinal stem cells; mesenchymal stem cells; stem cell transplantation

Indexed keywords

ADIPOCYTE; BONE MARROW TRANSPLANTATION; CARTILAGE CELL; CELL LINEAGE; CELL THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY BOWEL DISEASE; INTESTINAL STEM CELL; INTESTINE EPITHELIUM; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSTEOCYTE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BIOLOGICAL THERAPY; CYTOLOGY; HEMATOPOIETIC STEM CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; MESENCHYMAL STROMA CELL;

TUMOR NECROSIS FACTOR;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84979084486     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1177019     Document Type: Review

References (89)

1. G.G.Kaplan The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727. doi:10.1038/nrgastro.2015.150.
2. A.Kaser, S.Zeissig, R.S.Blumberg. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621. doi:10.1146/annurev-immunol-030409-101225.
3. W.J.Sandborn, S.B.Hanauer. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–133. doi:10.1097/00054725-199905000-00008.
4. A.C.Ford, W.J.Sandborn, K.J.Khan, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659–quiz660. doi:10.1038/ajg.2011.73.
5. G.R.Lichtenstein, P.Rutgeerts. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338–346. doi:10.1002/ibd.21253.
6. K.F.Frøslie, J.Jahnsen, B.A.Moum, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422. doi:10.1053/j.gastro.2007.05.051.
7. S.Ardizzone, A.Cassinotti, P.Duca, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–3. doi:10.1016/j.cgh.2010.12.028.
8. M.F.Neurath, S.P.L.Travis. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635. doi:10.1136/gutjnl-2012-302830.
9. J.Côté-Daigneault, M.Bouin, R.Lahaie, et al. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3:419–428. doi:10.1177/2050640615590302.
10. I.V.Pinchuk, R.C.Mifflin, J.I.Saada, et al. Intestinal mesenchymal cells. Curr Gastroenterol Rep. 2010;12:310–318. doi:10.1007/s11894-010-0135-y.
11. D.W.Powell, I.V.Pinchuk, J.I.Saada, et al. Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol. 2011;73:213–237. doi:10.1146/annurev.physiol.70.113006.100646.
12. Y.Nemoto, T.Kanai, S.Makita, et al. Bone marrow retaining colitogenic CD4+ T cells may be a pathogenic reservoir for chronic colitis. Gastroenterology. 2007;132:176–189. doi:10.1053/j.gastro.2006.10.035.
13. Y.Nemoto, T.Kanai, K.Kameyama, et al. Long-lived colitogenic CD4+ memory T cells residing outside the intestine participate in the perpetuation of chronic colitis. J Immunol. 2009;183:5059–5068. doi:10.4049/jimmunol.0900838.
14. R.K.Burt, A.Traynor, Y.Oyama, et al. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood. 2003;101:2064–2066. doi:10.1182/blood-2002-07-2122.•• This research article describes the initial study of HSC transplantation to refractory Crohn’s disease.
15. W.Kreisel, K.Potthoff, H.Bertz, et al. Complete remission of Crohn’s disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant. 2003;32:337–340. doi:10.1038/sj.bmt.1704134.
16. R.Scimè, A.M.Cavallaro, S.Tringali, et al. Complete clinical remission after high-dose immune suppression and autologous hematopoietic stem cell transplantation in severe Crohn’s disease refractory to immunosuppressive and immunomodulator therapy. Inflamm Bowel Dis. 2004;10:892–894. doi:10.1097/00054725-200411000-00027.
17. Y.Oyama, R.M.Craig, A.E.Traynor, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology. 2005;128:552–563. doi:10.1053/j.gastro.2004.11.051.
18. B.A.Lashner. Autologous hematopoietic stem cell transplantation for Crohn’s disease: high risk for a high reward. Inflamm Bowel Dis. 2005;11:778–779. doi:10.1097/01.MIB.0000171286.88690.ec.
19. A.Cassinotti, C.Annaloro, S.Ardizzone, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut. 2008;57:211–217. doi:10.1136/gut.2007.128694.
20. M.Clerici, A.Cassinotti, F.Onida, et al. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn’s disease. Dig Liver Dis. 2011;43:946–952. doi:10.1016/j.dld.2011.07.021.
21. R.K.Burt, R.M.Craig, F.Milanetti, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010;116:6123–6132. doi:10.1182/blood-2010-06-292391.
22. D.W.Hommes, M.Duijvestein, Z.Zelinkova, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn’s disease. J Crohns Colitis. 2011;5:543–549. doi:10.1016/j.crohns.2011.05.004.
23. J.A.Snowden, A.Ansari, S.Sachchithanantham, et al. Autologous stem cell transplantation in severe treatment-resistant Crohn’s disease: long-term follow-up of UK patients treated on compassionate basis. QJM. 2014;107:871–877. doi:10.1093/qjmed/hcu095.
24. A.Jauregui-Amezaga, M.Rovira, P.Marín, et al. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn’s disease. Gut. 2015. doi:10.1136/gutjnl-2015-309836. [Epub ahead print]
25. C.J.Hawkey, M.Allez, M.M.Clark, et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA. 2015;314:2524–2534. doi:10.1001/jama.2015.16700.• The latest phase III Randomized clinical trial of HSC transplantation to refractory Crohn’s disease.
26. A.R.Williams, J.M.Hare. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923–940. doi:10.1161/CIRCRESAHA.111.243147.
27. R.Onishi, S.Ohnishi, R.Higashi, et al. Human amnion-derived mesenchymal stem cell transplantation ameliorates dextran sulfate sodium-induced severe colitis in rats. Cell Transplant. 2015;24:2601–2614. doi:10.3727/096368915X687570.
28. S.Ishikane, S.Ohnishi, K.Yamahara, et al. Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells. 2008;26:2625–2633. doi:10.1634/stemcells.2008-0236.
29. J.A.Ankrum, J.F.Ong, J.M.Karp. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32:252–260. doi:10.1038/nbt.2816.
30. E.E.Mahmoud, G.Kamei, Y.Harada, et al. Cell magnetic targeting system for repair of severe chronic osteochondral defect in a rabbit model. Cell Transplant. 2015. doi:10.3727/096368915X689613. [Epub ahead print]
31. V.Karantalis, V.Y.Suncion-Loescher, L.Bagno, et al. Synergistic effects of combined cell therapy for chronic ischemic cardiomyopathy. J Am Coll Cardiol. 2015;66:1990–1999. doi:10.1016/j.jacc.2015.08.879.
32. F.Casiraghi, N.Perico, M.Cortinovis, et al. Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nat Rev Nephrol. 2016;12:241–253. doi:10.1038/nrneph.2016.7.
33. C.Chen, J.Hou. Mesenchymal stem cell-based therapy in kidney transplantation. Stem Cell Res Ther. 2016;7:16. doi:10.1186/s13287-016-0283-6.
34. M.A.Antunes, J.G.Laffey, P.Pelosi, et al. Mesenchymal stem cell trials for pulmonary diseases. J Cell Biochem. 2014;115:1023–1032. doi:10.1002/jcb.24783.
35. J.Cai, Z.Wu, X.Xu, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes Care. 2016;39:149–157. doi:10.2337/dc15-0171.
36. L.-X.Guan, H.Guan, H.-B.Li, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015;9:1623–1630. doi:10.3892/etm.2015.2355.
37. S.Oraee-Yazdani, M.Hafizi, A.Atashi, et al. Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord. 2016;54:102–109. doi:10.1038/sc.2015.142.
38. A.Owen, P.N.Newsome. Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt? Am J Physiol Gastrointest Liver Physiol. 2015;309:G791–800.
39. K.Muroi, K.Miyamura, M.Okada, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103:243–250. doi:10.1007/s12185-015-1915-9.
40. J.-F.Li, D.-J.Zhang, T.Geng, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23(Suppl 1):S113–S122. DOI:10.3727/096368913X673450.
41. A.Cras, D.Farge, T.Carmoi, et al. Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Arthritis Res Ther. 2015;17:301. doi:10.1186/s13075-015-0819-7.
42. F.Tanaka, K.Tominaga, M.Ochi, et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 2008;83:771–779. doi:10.1016/j.lfs.2008.09.016.
43. B.Parekkadan, R.Upadhyay, J.Dunham, et al. Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes. Gastroenterology. 2011;140:966–975. doi:10.1053/j.gastro.2010.10.013.
44. T.Yabana, Y.Arimura, H.Tanaka, et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol. 2009;218:350–359. doi:10.1002/path.2535.
45. H.Tanaka, Y.Arimura, T.Yabana, et al. Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat. J Gastroenterol. 2011;46:143–152. doi:10.1007/s00535-010-0320-7.
46. S.Watanabe, Y.Arimura, K.Nagaishi, et al. Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors. J Gastroenterol. 2014;49:270–282. doi:10.1007/s00535-013-0895-x.
47. K.Nagaishi, Y.Arimura, M.Fujimiya. Stem cell therapy for inflammatory bowel disease. J Gastroenterol. 2015;50:280–286. doi:10.1007/s00535-015-1040-9.•• This review covers the recent knowledge of the mechanism how MSC can promote tissue repair and adjust the host immune response in IBD models and patients.
48. E.Sala, M.Genua, L.Petti, et al. Mesenchymal stem cells reduce colitis in mice via release of TSG6, independently of their localization to the intestine. Gastroenterology. 2015;149:163–176.e20. doi:10.1053/j.gastro.2015.03.013.
49. H.Choi, R.H.Lee, N.Bazhanov, et al. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood. 2011;118:330–338. doi:10.1182/blood-2011-02-334870.
50. P.A.Sotiropoulou, S.A.Perez, A.D.Gritzapis, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells J. 2006;24:74–85. doi:10.1634/stemcells.2004-0359.
51. M.Krampera, L.Cosmi, R.Angeli, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–398. doi:10.1634/stemcells.2005-0008.
52. J.G.Casado, R.Tarazona, F.M.Sanchez-Margallo. NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity. Stem Cell Rev. 2013;9:184–189. doi:10.1007/s12015-013-9430-y.
53. I.K.Ko, B.-G.Kim, A.Awadallah, et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther. 2010;18:1365–1372. doi:10.1038/mt.2010.54.
54. S.Ghannam, J.Pène, G.Moquet-Torcy, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302–312. doi:10.4049/jimmunol.0902007.
55. I.Prigione, F.Benvenuto, P.Bocca, et al. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells. 2009;27:693–702. doi:10.1634/stemcells.2008-0687.
56. I.Rasmusson, K.Le Blanc, B.Sundberg, et al. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol. 2007;65:336–343. doi:10.1111/j.1365-3083.2007.01915.x.
57. E.Svobodova, M.Krulova, A.Zajicova, et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev. 2012;21:901–910. doi:10.1089/scd.2011.0157.
58. M.Duijvestein, A.C.W.Vos, H.Roelofs, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 2010;59:1662–1669. doi:10.1136/gut.2010.215152.
59. G.M.Forbes, M.J.Sturm, R.W.Leong, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64–71. doi:10.1016/j.cgh.2013.06.021.
60. N.A.Manieri, M.R.Mack, M.D.Himmelrich, et al. Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis. J Clin Invest. 2015. DOI:10.1172/JCI81423–13.
61. R.Ciccocioppo, M.E.Bernardo, A.Sgarella, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788–798. doi:10.1136/gut.2011.237727.
62. Y.B.Cho, K.J.Park, S.N.Yoon, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4:532–537. doi:10.5966/sctm.2014-0199.•• This research article shows the recent study regarding the long-term outcome of MSC transplantation to fistulizing Crohn’s disease patients.
63. R.Ciccocioppo, A.Gallia, A.Sgarella, et al. Long-term follow-up of Crohn disease fistulas after local injections of bone marrow-derived mesenchymal stem cells. Mayo Clin Proc. 2015;90:747–755. doi:10.1016/j.mayocp.2014.12.011.
64. W.Y.Lee, K.J.Park, Y.B.Cho, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31:2575–2581. doi:10.1002/stem.1357.
65. K.B.Gecse, W.Bemelman, M.A.Kamm, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014:1381–1392. doi:10.1136/gutjnl-2013-306709.
66. N.Barker, M.Van De Wetering, H.Clevers. The intestinal stem cell. Genes Dev. 2008;22:1856–1864. doi:10.1101/gad.1674008.
67. R.Okamoto, M.Watanabe. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2015;51:11–21. doi:10.1007/s00535-015-1098-4.
68. T.Sato, J.H.Van Es, H.J.Snippert, et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature. 2012;469:415–418. doi:10.1038/nature09637.
69. H.Shimizu, R.Okamoto, G.Ito, et al. Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine. Peer J. 2014;2:e370. doi:10.7717/peerj.246.
70. K.L.VanDussen, A.J.Carulli, T.M.Keeley, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. Development. 2012;139:488–497. doi:10.1242/dev.076851.
71. R.Okamoto, K.Tsuchiya, Y.Nemoto, et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol. 2009;296:G23–G35. doi:10.1152/ajpgi.90225.2008.
72. A.Gregorieff, Y.Liu, M.R.Inanlou, et al. Yap-dependent reprogramming of Lgr5+ stem cells drives intestinal regeneration and cancer. Nature. 2015;526:715–718. doi:10.1038/nature15382.
73. T.Sato, D.E.Stange, M.Ferrante, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141:1762–1772. doi:10.1053/j.gastro.2011.07.050.• The first report showing the method for sustained in vitro culture of ISCs.
74. T.Sato, R.G.Vries, H.J.Snippert, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–265. doi:10.1038/nature07935.
75. T.Sato, H.Clevers, H.Clevers. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science. 2013;340:1190–1194. doi:10.1126/science.1234852.
76. Vandussen K, Marinshaw JM, Shaikh N, et al. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64:911–920.
77. S.Middendorp, K.Schneeberger, C.L.Wiegerinck, et al. Adult stem cells in the small intestine are intrinsically programmed with their location-specific function. Stem Cells. 2014;32:1083–1091. doi:10.1002/stem.1655.
78. S.Yui, T.Nakamura, T.Sato, et al. Functional engraftment of colon epithelium expanded in vitro from a single adult Lgr5⁺ stem cell. Nat Med. 2012;18:618–623. doi:10.1038/nm.2695.• The first report showing the proof-of-concept of ISC transplantation using an IBD model.
79. R.P.Fordham, R.P.Fordham, S.Yui, et al. Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell. 2013;13:734–744. doi:10.1016/j.stem.2013.07.010.
80. M.Fukuda, T.Mizutani, W.Mochizuki, et al. Small intestinal stem cell identity is maintained with functional Paneth cells in heterotopically grafted epithelium onto the colon. Genes Dev. 2014;28:1752–1757. doi:10.1101/gad.245233.114.
81. R.Okamoto, M.Watanabe. Perspectives for regenerative medicine in the treatment of inflammatory bowel diseases. Digestion. 2015;92:73–77. doi:10.1159/000438663.
82. C.E.Matisz, G.Leung, J.L.Reyes, et al. Adoptive transfer of helminth antigen-pulsed dendritic cells protects against the development of experimental colitis in mice. Eur J Immunol. 2015;45:3126–3139. doi:10.1002/eji.201545579.
83. H.Zigdon-Giladi, T.Bick, D.Lewinson, et al. Co-transplantation of endothelial progenitor cells and mesenchymal stem cells promote neovascularization and bone regeneration. Clin Implant Dent Relat Res. 2015;17:353–359. doi:10.1111/cid.12104.
84. A.V.Vanikar, S.D.Dave, U.G.Thakkar, et al. Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int. 2010;2010:582382–582385. doi:10.4061/2010/582382.
85. U.G.Thakkar, A.V.Vanikar, H.L.Trivedi. Co-infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and bone marrow derived hematopoietic stem cells, a viable therapy for post-traumatic brachial plexus injury: a case report. Biomed J. 2014;37:237–240. doi:10.4103/2319-4170.132893.
86. Z.Chen, X.He, X.He, et al. Bone marrow mesenchymal stem cells ameliorate colitis-associated tumorigenesis in mice. Biochem Biophys Res Commun. 2014;450:1402–1408. doi:10.1016/j.bbrc.2014.05.144.
87. M.Nasuno, Y.Arimura, K.Nagaishi, et al. Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Stem Cells. 2014;32:913–925. doi:10.1002/stem.1594.
88. S.Danese, A.Malesci, S.Vetrano. Colitis-associated cancer: the dark side of inflammatory bowel disease. Gut. 2011;60:1609–1610. doi:10.1136/gut.2011.237727.
89. S.I.Grivennikov. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2012;35:229–244. doi:10.1007/s00281-012-0352-6.